Oct 16, 2024 Vedanta Biosciences To Present at IDWeek 2024 on Benefit of VE303 on Antibiotic Resistant Gene Levels in Patient Microbiomes
May 21, 2024 Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection
Apr 30, 2024 Vedanta Biosciences Awarded $3.9 Million from CARB-X to Ready VE707 for First-in-Human Study for Prevention of Multidrug-Resistant Infections
Mar 6, 2024 Vedanta Biosciences to Host Investor Meetings at the Leerink Partners 2024 Global Biopharma Conference
Nov 28, 2023 Vedanta Biosciences’ Key Microbiome Patents Fully Upheld in Three European Opposition Proceedings
Nov 13, 2023 Topline Data of Investigator-Sponsored Study of VE303 to Treat Hepatic Encephalopathy (HE) Presented at The Liver Meeting 2023
Oct 30, 2023 Vedanta Biosciences to Host Investor Meetings at the Wells Fargo Virtual Private Biotech Symposium
Oct 11, 2023 Vedanta Biosciences Presents Progress from Two Defined Bacterial Consortia, VE303 for the Prevention of C. difficile and VE707 for the Prevention of Gram-Negative Infections, at IDWeek 2023
